Thetis Pharmaceuticals Announces Patent Grants for TP-317, Extending Protection to Japan and Brazil

Japan and Brazil Join the United States as Issued Jurisdictions for the TP-317 Cyclodextrin Patent Family, with Applications Pending in Europe, China, and Other Major Markets

 ESSEX, Conn. — September 8, 2026 — Thetis Pharmaceuticals, LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, oral BLT1 agonist for inflammatory bowel disease (IBD), today announced that the Japan Patent Office and the Brazilian National Institute of Industrial Property have granted patents in the TP-317 cyclodextrin patent family: Japanese Patent No. 7891079, entitled “Cyclodextrin Complexes of Specialized Proresolving Mediators,” and Brazilian Patent No. BR 112024018088-3, entitled (in translation) “Complex of Resolvin E1 (RvE1), or a Salt, Ester or Amide Thereof, and a Gamma-Cyclodextrin (Gamma-CD), and Pharmaceutical Composition.” The patents have a base expiration date in March 2043, and the Japanese patent is eligible for patent term extension.

RvE1 is a naturally unstable molecule. TP-317 complexed with gamma-cyclodextrin protects it from degradation, enabling pharmaceutical development of RvE1 formulated as an oral tablet.

“The grants in Japan and Brazil, following our U.S. patent earlier this year, confirm the global reach of the TP-317 patent family,” said Gary Mathias, co-founder and CEO of Thetis. “From the outset, we have built our intellectual property to support the development and commercialization of TP-317 in the world’s major pharmaceutical markets.”

About Thetis Pharmaceuticals

Thetis is a clinical-stage pharmaceutical company focused on developing new therapies for IBD and oncology. Thetis' lead candidate, TP-317, is a first-in-class, oral Resolvin E1 (RvE1) drug candidate that engages the BLT1 receptor to activate the body’s natural ability to restore tissue and immune homeostasis. In a Phase 1a study, TP-317 was well tolerated and demonstrated target engagement. A Phase 1b proof-of-mechanism trial in moderate-to-severe ulcerative colitis patients will begin recruiting in Q4-2026.  Thetis is supported by the Helmsley Charitable Trust, the Crohn's & Colitis Foundation, the Kenneth Rainin Foundation, the National Institutes of Health (NIH), and private investors.

Contact Information

Tracy Lessor
TLOW Communications
617-519-9827
tracy@tlowcommunications.com